Microbix Biosystems Inc (OTCPK:MBXBF)

Q1 2025 Microbix Biosystems Inc Earnings Call Transcript

Feb 13, 2025 / 04:00 PM GMT

Release Date Price: $0.34 (-0.32%)

Transcript

Key Points

Positve

Microbix Biosystems Inc (MBXBF) reported strong revenue growth from recurring sales, reaching over $6 million, compared to $4.3 million in the prior year, excluding non-recurring milestone payments.
The company achieved significant gross margin expansion to 62% from 49% in the previous year, reflecting improved manufacturing efficiencies.
Microbix Biosystems Inc (MBXBF) successfully expanded its total addressable markets by entering the genetic testing and oncology sectors, enhancing future growth potential.
The company has initiated a recombinant antigen program, which is expected to significantly expand its market opportunities and drive future growth.
Microbix Biosystems Inc (MBXBF) maintained a strong cash position, bolstered by warrant and option exercises, providing financial flexibility for future initiatives.

Negative

The company's revenue was impacted by a transient reduction in activity from a test manufacturer, affecting caps revenue.
There is uncertainty regarding the timing of new assay launches, which could affect future revenue projections.
The transition to recombinant antigens may present challenges in maintaining margins comparable to native antigens.
Operating expenses may experience slight increases due to cost of living adjustments and inflationary pressures.
Potential tariffs could impact margins by 2-4%, depending on the extent of countervailing tariffs and supply chain adjustments.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MBX.TO - Microbix Biosystems Inc
Q1 2025 Microbix Biosystems Inc Earnings Call
Feb 13, 2025 / 04:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning, everyone. Thanks for joining us today. We have a presentation with Micromic Bio Systems where we're going to go through their physical Q1 results. With me today I have Cameron Groom, CEO Jim Curry, CFO, Ken Hughes, COO.

Before we jump into everything, I don't think we're going to work off a presentation, but just so everyone's aware, this session will contain forward-looking statements. If you'd like to know more about those, you can find them on the company's presentation on the website, which will be updated today at some point.

And the session will consist of a bit of an overview of the corner from management, and then we'll jump into Q&A. So feel free to put any questions you have in the Q

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.